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A CE assay for the detection of agonist-
stimulated adenylyl cyclase activity
A CE assay was developed for the detection of adenylyl cyclase (AC) activity stimulated at
the AC and G protein-coupled receptor (GPCR) level. In the assay, cell membranes over-
expressing GPCR and/or AC were incubated with modulators and substrate ATP to produce
cAMP in a dose-dependent manner. In both the CE-UV and a radiochemical assay, the
addition of forskolin (FSK) resulted in a two- to three-fold maximum increase in AC activity
with EC50s of 4.2 6 0.7 and 2.4 6 0.7 mM, respectively, demonstrating that similar results
were obtained by both assays. GPCR activation was also detected using cell membranes
overexpressing AC and the b2-adrenergic receptor (b2AR) fused to the stimulatory G pro-
tein. Terbutaline (b2AR agonist) increased the basal rate of cAMP formation 1.7 6 0.1-fold
resulting in an EC50 of 62 6 10 nM. The assay’s ability to detect antagonists is demon-
strated by the expected right-shifted EC50 of terbutaline by the b2AR antagonist propranolol.
The CE-UV assay offers advantages over the traditional radioactivity assay in terms of safety
and labor.
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1 Introduction
The G protein signaling cascade is initiated by an extra-
cellular ligand (or drug) binding to a membrane-bound G
protein-coupled receptor (GPCR). The ligand-binding event
causes a conformational change in the associated intracel-
lular G proteins that further activate downstream effectors
such as adenylyl cyclase (AC). Over 50% of current drugs
target GPCRs [1], and GPCRs are implicated in many condi-
tions including addiction [2], heart failure [3], and infection
by the human immunodeficiency virus [4, 5]. More recently,
AC has also been viewed as a drug target based on its
involvement in Alzheimer’s [6], diabetes [7], and addiction [8,
9]. Novel, rapid, and robust assays are required for ligand
screening and drug discovery at both of these signal trans-
duction targets.
AC converts ATP to the second messenger cAMP, and
therefore ligands directly targeting AC can be studied by
monitoring this enzymatic reaction. A common approach to
detect GPCR activation is to monitor a downstream bio-
chemical reaction that results from binding of ligands to the
GPCR. For example, GPCR activation may be detected by
monitoring the activation of AC by stimulatory G proteins
(Gas) coupled to the GPCR [10–14]. An advantage of mon-
itoring AC activity for GPCR studies is that it is often more
sensitive than assays upstream of the biochemical pathway,
such as [35S]GTPgS binding, due to signal amplification [12,
15]. Therefore, the same AC assay can be used to monitor
ligands binding to GPCRs or AC.
The most common method for detecting AC activity uses
radioactive substrate as a tracer and ion-exchange chroma-
tography to separate the product from substrate and side-
product nucleotides (AMP and ADP) [16, 17]. Although sen-
sitive and reliable, this technique is slow, labor intensive, and
uses radioactivity, which adds danger and cost to the assay.
Desire for a safer, nonradioactive assay led to the develop-
ment and commercialization of enzyme immunoassays
(EIAs) for cAMP [18–20] to probe AC activity, but the limited
dynamic range, expense, and time associated with the EIA
make it impractical for everyday use. Several other assay
platforms have also been commercialized and have been
recently reviewed, including the use of radio- or fluorescently
labeled cAMP to compete with cAMP formed in the assay in
a competitive immunoassay format [12, 21, 22]. Drawbacks
of commercially available assays include requirements for
special reagents (antibodies and/or labeled cAMP), time-
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consuming filtering steps, or custom endpoint detectors, all
of which add expense to the assay. An ideal assay would
eliminate the requirements for radioactivity and expensive
reagents with limited shelf lives. One possibility would be to
use native ATP as the substrate and a high-resolution
separation technique, such as CE, to resolve the substrate
from product (cAMP).
CE has emerged as a valuable tool for measuring the
enzymatic activity due to low volume sample requirements,
rapid analysis times, high-resolution separations, and ease-
of-use (for reviews, see [23–25]). Many variations of the CE
enzyme assay have been reported [23], but the simplest
involves off-line incubation of substrate–enzyme mixture
followed by injection and separation. The different charge-to-
size ratios of cAMP and ATP suggest that CE could poten-
tially be a valuable addition to the armamentarium of tech-
niques used to measure AC activity.
In this work, CE was used to measure AC activation in
membranes from Spodoptera frugiperda (fall armyworm, Sf9)
cells expressing AC or coexpressing the b2-adrenergic recep-
tor (b2AR) fused to GasL (a long splice variant of Gas) and
AC. CE is used to detect the conversion of ATP to cAMP fol-
lowing the addition of drugs that act either at the GPCR or
directly at AC. The technique offers a more rapid and auto-
matable approach to detect AC activity, and has promise to be
scaled up for use in high-throughput screening.
2 Materials and methods
2.1 Materials
Sf9 cells were purchased from Invitrogen (Carlsbad, CA). Tris-
HCl, sodium phosphate monobasic monohydrate, and
MgCl2?6H2O were purchased from Fisher (Fair Lawn, NJ,
USA). Forskolin (FSK; from Coleus forskohlii) was purchased
from Calbiochem (San Diego, CA, USA) and Ro 20-1724 was
purchased from A.G. Scientific (San Diego, CA, USA).
[a-32P]ATP and [3H]cAMP were purchased form Perkin-Elmer.
(6)-Propranolol, (2)-isoproterenol, terbutaline, and all the
other materials were purchased from Sigma (St. Louis, MO,
USA). Buffers were made in deionized water purified by E-Pure
water systems (Barnstead International, Dubuque, IA, USA).
2.2 Protein expression and purification
Cytosolic AC domains VC1 (isoform V, first cytosolic domain)
and ArgC-IIC2 (IIC2, isoform II, second cytosolic domain)
were expressed and purified as previously described [26, 27]
and stored at 2807C until use.
2.3 Membrane preparations
Sf9 cells (cell density of 1.6–1.86106 cells/mL) were infected
with viruses containing the cDNAs for AC2 alone (AC) or a
fusion of b2AR and GasL (b2ARGasL) [28] and AC2
(b2ARGasL-AC) and incubated at 277C under rotation. The
AC2 virus was a kind gift from A. G. Gilman (University of
Texas Southwestern Medical Center). Cells were harvested
48–72 h post infection in buffer containing 50 mM Tris-HCl
pH 8.0, 150 mM NaCl, and protease inhibitors (32 mg/mL
each of N-tosyl-L-phenylalanine chloromethyl ketone and N-
a-P-tosyl-L-lysine chloromethyl ketone, 35 mg/mL phe-
nylmethylsulfonylfluoride, and 3.2 mg/mL each of leupeptin
and soybean trypsin inhibitor) and lysed by nitrogen cavita-
tion using a Parr bomb (600 psi, 30 min). Unlysed cells were
removed by a low speed spin (20006g, 10 min), and mem-
branes were collected following ultracentrifugation
(100 0006g, 35 min). Membranes were diluted in 50 mM
Tris-HCl pH 8.0, 50 mM NaCl, and protease inhibitors (same
as above) and protein concentrations were determined by the
Bradford Assay (BioRad Laboratories, Hercules, CA, USA).
With the exception of the cell infection, all the steps were
performed at 47C. Aliquots were snap frozen in liquid nitro-
gen and stored at 2807C. Thawed samples were homoge-
nized (Kimble Kontes, Vineland, NJ, USA) prior to use.
2.4 Adenylyl cyclase assays for purified AC
Samples containing 1 mM AC (1 mM VC1 and 7.6 mM IIC2)
and 1 mM ATP were incubated with or without 100 mM FSK
in buffer containing 10 mM Tris-HCl pH 8.0, 1 mM EDTA,
5 mM MgCl2, and 1 mM DTT. Samples were maintained at
257C and were not prepared in a regeneration system be-
cause endogenous ATPase and phosphodiesterases (PDEs)
were absent.
2.5 Adenylyl cyclase assays for membrane-bound AC
2.5.1 Radioactivity assay
AC assays were performed as previously described [16, 26,
28, 29]. Briefly, 25–100 mg of membrane was incubated with
modulators in 10 mM Tris-HCl pH 8.0, 1 mM EDTA, and
5 mM MgCl2 for 30 min on ice with a final volume of 50 mL.
The reaction was initiated by the addition of 50 mL of activa-
tion buffer (20 mM Tris-HCl pH 8.0, 3 mM potassium
phosphoenolpyruvate, 100 mM Ro 20-1724, 0.6 mM EDTA,
5 mM MgCl2, 50 mg/mL pyruvate kinase, 2 mM ATP, and
,106 cpm [a-32P]ATP), and membranes were incubated for
30 min at 307C, unless otherwise indicated. The reaction was
quenched with buffer containing 0.25% SDS, 5 mM ATP,
and 0.175 mM cAMP and nucleotides were separated with
Dowex and alumina columns. [3H]-cAMP was used as the
internal standard to account for column recovery variation.
2.5.2 CE assay
Samples were prepared the same as above with the excep-
tions of the elimination of radiolabeled ATP and reactions
being quenched with 2 mL of 500 mM EDTA
([EDTA]final = 10 mM). The autosampler was at 307C when
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kinetic studies were performed on-line. Bovine Gas was
expressed in Escherichia coli, purified and preactivated with
GTPgS as previously described [30]. Thymidine was used as
the internal standard.
2.6 CE with UV detection
A PACE/MDQ CE unit (Beckman Coulter, Fullerton, CA,
USA) was used to separate nucleotides using a 75 mm inner
diameter, 360 mm outer diameter fused-silica capillary (Poly-
micro Technologies, Phoenix, AZ, USA) with an effective
length of 20 cm and a total length of 30 cm. Absorbance was
measured at 254 nm. The autosampler was maintained at
47C for all the experiments unless otherwise noted. Data
acquisition (16 Hz) and control were performed using
P/ACE 32 Karat Software Version 5.0 (Beckman) for Win-
dows 2000 on a 2.0 GHz IBM personal computer.
For experiments using purified cytosolic domains,
separation buffer was 20 mM sodium phosphate, pH 8.8.
For experiments using membrane-bound AC, separation
buffer was 20 mM sodium phosphate, 10 mM EDTA
pH 10.3. At the beginning of each day, capillary was rinsed
with 0.1 M NaOH, H2O, and separation buffer for 5 min
each. Between separations, the capillary was rinsed with
0.1 M NaOH and electrophoresis buffer for 1 min each prior
to injection. Unfiltered samples were injected for 3 s at
0.5 psi and separation was at 15 kV (500 V/cm) and 10 kV
(333 V/cm) for experiments using purified and membrane-
bound AC, respectively.
2.7 Data analysis
CE data were analyzed with Cutter 7, software written in-
house [31]. The amount of cAMP produced in the CE assay
was quantified using a calibration curve of cAMP standards.
For the radioactivity assay, cAMP was quantified using scin-
tillation counting as described elsewhere [17]. EC50 values
were determined by fitting dose–response data using Graph-
Pad Prism (Version 3.0, GraphPad Software, San Diego, CA,
USA) to y = Bottom 1 [(Top-Bottom)/(1 1 10LogEC50-x)] where
x is the logarithmic concentration of the activator in M and y is
the rate of cAMP formation. Each dose–response experiment
was performed in quadruplicate and similar EC50 values were
obtained. Error is reported as 6 S.E.M.
3 Results and discussion
Our goal was to develop a radioactive-free, rapid, and robust
CE assay for the detection of AC activity. The assay was initi-
ally demonstrated with purified AC before being extended to
cell membranes overexpressing AC to better mimic AC’s
physiological environment. After the assay was optimized for
cell membranes, AC drugs were detected using membranes
overexpressing AC, then GPCR drugs were detected using
membranes overexpressing GPCR and AC.
3.1 Detection of AC activity using purified AC
Initial experiments used purified cytosolic domains of AC
and monitored the conversion of ATP to cAMP under basal
and FSK-stimulated conditions. The cytosolic domains con-
tain the active site, and previous studies have used the cyto-
solic domains to model membrane-bound AC [27, 32]. When
cytosolic domains of AC were incubated with ATP and the
resulting mixture separated by CE, peaks corresponding to
product (cAMP, t = 1.9 min) and substrate (ATP, t = 3.7 min)
were observed (Fig. 1A), validating the assay’s ability to detect
AC activity. (The identity of the cAMP and ATP peaks was
confirmed by spiking in standards.) The small sample
volumes associated with CE allowed the same sample to be
serially injected for measuring the rate of cAMP formation.
Figure 1B demonstrates that linear rates can be monitored
under basal conditions (inset). When AC was stimulated
with FSK, the rate of cAMP formation increased as expected,
but rapidly deviated from linearity (Fig. 1B). When product
and substrate were monitored with time under these condi-
tions (Fig. 1C), it became apparent that the deviation from
linearity was due to rapid substrate depletion. It was also
noted that the amount of cAMP formed plus ATP remaining
was not constant throughout the 100 min reaction (Fig. 1C).
This was not likely due to the formation of side products as
none were detected. It is partially due to a lower extinction
coefficient for cAMP (12.36103/M/cm) [33] than ATP
(15.46103/M/cm) [34], resulting in a decrease in the total
peak area as the amount of cAMP formed increased. In view
of the narrower peaks for cAMP than ATP, the decrease in
total area may also be partially due to using a concentration-
sensitive detector, which can yield smaller peak areas for a
given mass injected if the peak is narrower.
3.2 Assay optimization for detecting AC activity in
cell membranes
When measuring AC activity in cell membranes, modifica-
tions to the assay must be made to account for endogenous
ATPase and PDE activities [17]. ATPases convert ATP to ADP
and AMP resulting in substrate depletion and nonlinear
rates of product formation. PDEs convert cAMP to AMP
making the detection of cAMP difficult if not impossible. To
compensate for ATPase activity, ATP-regeneration systems
(such as pyruvate kinase/phosphoenol pyruvate) are com-
monly used to regenerate ATP from ADP and AMP, ensur-
ing a constant substrate supply [35, 36]. PDE activity is pre-
vented by the addition of PDE inhibitors such as Ro 20-1724,
allowing accumulation and detection of cAMP.
All nucleotides must be well resolved to ensure proper
functioning of the regeneration system and PDE inhibitors.
The separation conditions used for the experiments involv-
ing purified AC cytosolic domains were sufficient for the
separation of cAMP and ATP (samples lacked endogenous
ATPases and PDEs and therefore separating ADP from ATP
was not a concern). A change in separation conditions was
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Figure 1. Purified cytosolic domains validate the use of the
CE-UV assay to monitor AC activity. All the samples contained
1 mM AC and 1 mM ATP. (A) Electropherogram of sample con-
taining AC, ATP, and 100 mM forskolin after 4 min of reaction. (B)
Samples containing AC, and 0 mM (n) or 100 mM forskolin (s)
were serially injected and cAMP was monitored with time. The
inset is a blowup of the linear cAMP formation under non-
stimulated (0 mM forskolin) conditions. (C) ATP and cAMP were
monitored with time in sample containing AC, ATP, and 100 mM
forskolin. The y-axis represents the peak area of ATP or cAMP
divided by the peak area of internal standard (IS).
required for analysis of AC activity in membranes because
ADP was not well resolved from ATP using the separation
conditions for purified AC. Addition of EDTA to the separa-
tion buffer was found to improve the resolution between the
nucleotides; however, this also increased the current result-
ing in slower EOF and longer migration times. To alleviate
some of the heating associated with the increased current,
the electric field was decreased to 333 V/cm, further con-
tributing to longer migration times.
3.3 Detection of basal AC activity in cell membranes
Using the improved sample and separation conditions,
detection of AC activity in cell membranes was attempted
using CE. Sf9 membranes containing overexpressed AC were
incubated with ATP (see Section 2) and cAMP was produced,
migrating at 3.3 min by CE, as shown in Fig. 2A. After
30 min of reaction, ,5 mM cAMP (or 133 fmol cAMP) was
formed. The identity of cAMP peak was confirmed by spik-
ing with standards. ATP migrated after cAMP at t = 9.0 min.
Both cAMP and ATP migrated at longer times than in Fig. 1A
because the separation buffer was changed to better resolve
the nucleotides (see above). After ,100 min of reaction time
(depending on the amount of protein used in the assay),
AMP and ADP were detected in the electropherogram
migrating between cAMP and ATP (data not shown). The
presence of these nucleotides indicated depletion of the PDE
inhibitor and regeneration system. Occasionally, spikes of
irreproducible migration time (denoted by asterisks in
Fig. 2A) were observed in electropherograms and were at-
tributed to the injection of membrane fragments or other
particulates from the unfiltered samples.
An important experiment when detecting enzyme activi-
ty is to ensure that the amount of product formed increases
linearly with the amount of protein in the sample. To test the
linearity of cAMP formation as a function of protein amount,
substrate was added to various amounts of AC membrane
and the amount of cAMP formed after a 30 min reaction was
measured. As expected, the amount of cAMP produced
increased linearly as a function of protein amount (Fig. 2B).
However, increasing protein amounts to above 75 mg/tube
also led to irreproducible migration times, making quantifi-
cation more difficult by increasing the peak area RSD from
4% (25 mg/tube) to 17% (100 mg/tube). For most of the
experiments, 25–75 mg protein/tube was used to achieve a
balance between signal strength and quantification repro-
ducibility.
To determine the assay’s utility for kinetic experiments,
sample containing AC membrane and ATP was serially
injected and cAMP formation monitored (Fig. 2C). The rapid
separation of substrate from enzyme in the capillary is used
to quench the reaction of the aliquot, allowing the sample
reaction to continue in the autosampler. In this way, the
sample can be repeatedly injected for the acquisition of
kinetic information, drastically reducing sample consump-
tion compared to kinetic studies using the radiochemical
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Figure 2. ATP is converted to cAMP upon interaction with AC. (A)
Electropherogram of sample containing AC membrane and ATP.
Spikes in the electropherogram (denoted by *) were the result of
membranes being injected. Thymidine was used as the internal
standard (IS) to account for injection volume variation. The inset
more clearly depicts the cAMP peak. (B) cAMP formation was
measured in samples containing 0–100 mg AC membrane. (C)
Sample containing AC and ATP was serially injected and cAMP
measured with time. At t = 100 min, 10 mM EDTA was added and
sample storage set to 47C to quench the reaction. All samples
contained 50 mg AC membrane and were incubated for 30 min at
307C unless otherwise indicated. CE conditions are described in
Section 2.
assay. Using serial injections, cAMP formation was mon-
itored with time and a linear increase in cAMP formation
was observed up to 100 min. To ensure cAMP rates were not
skewed by substrate depletion or depletion of the PDE in-
hibitor and/or regeneration system, reaction rates for all the
experiments were determined at 30 min unless otherwise
noted.
Some applications require only one measurement of
cAMP formation and quenching is required to stop the
reaction at a specified time. For example, in a drug screen-
ing experiment with numerous samples, the reaction is
allowed to proceed for a fixed time before being quenched;
the cAMP formed in each sample is then compared against
basal. AC is a Mg21-dependent enzyme and the addition of
excess EDTA is expected to quench cAMP formation.
Figure 2C shows that when 10 mM EDTA was added to the
sample after 100 min, the amount of cAMP present in the
sample remained constant with an RSD of 3%, confirming
the validity of quenching with EDTA. The consistency and
stability of the cAMP signal with time further validates pre-
paring numerous samples simultaneously and analyzing
one-by-one in an automated system over the course of sev-
eral hours.
3.4 Detection of AC stimulation and inhibition
Recently the use of AC as a therapeutic target has been pro-
posed [37–40], and therefore one of the goals was to detect
the modulation of AC activity with various drugs directly
targeting AC. These experiments were performed using
membrane-bound AC instead of purified AC to better mimic
AC’s physiological environment. To test if this assay could be
used to quantify the activation of AC in membranes, the rate
of cAMP formation was measured with and without 10 mM
FSK, an exogenous AC activator [41, 42]. Figure 3A shows
that FSK increased the rate of cAMP formation two-fold from
0.2 to 0.4 nmol/mg/min. To compare the results obtained by
the CE-UV and radioactivity techniques, parallel assays were
performed to measure the rate of cAMP formation in
membranes with increasing amounts of FSK. Fitting the
CE-UV data to a dose–response curve resulted in an
EC50 = 4.2 6 0.7 mM (n = 4) as shown in Fig. 3B. This EC50
value was similar to that observed using the radioactivity
assay (Fig. 3B, EC50 = 2.4 6 0.7 mM, n = 4). The EC50 values
obtained by both techniques agree well with the literature
value of 5–10 mM [43]. Furthermore, a similar two- to three-
fold maximal increase in activity was observed by both tech-
niques. Although similar EC50s and maximal increases were
obtained for the two techniques, differences in basal rates
were observed. Discrepancies in basal rates could be due to
variations in the experimental procedure (e.g., incubation
temperature variations, protein lability, or variation in sub-
strate/internal standard addition), or differences in the
method of cAMP quantification. (The CE-UV assay quanti-
fied using a cAMP calibration curve, whereas the radio-
activity assay used here multiplied [32P]cAMP formed by the
unlabeled/labeled ATP dilution factor to quantify the cAMP
produced [17]. Dilution error and/or detector differences
could attribute to differences in cAMP quantification.) Com-
paring the two assays, it appears that the CE-UV assay has
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Figure 3. Rates of cAMP formation can be modulated with AC
drugs. (A) Addition of 10 mM forskolin (FSK, m) to 50 mg AC
membrane increased the basal (u) rate of cAMP formation. (B)
AC activity was determined in samples containing 75 mg AC (CE-
UV) or 25 mg AC (radioactivity), ATP, and 0–100 mM forskolin.
Results are representative of four independent experiments for
each type of assay. (C) Samples containing 75 mg AC membranes
were incubated with ATP and 10 mM forskolin (FSK), 5 nM Gas-
GTPgS (Gas-GTPgS), or 25 mM 20,50-dd-30-ADP (dd-30-ADP) and the
rate of cAMP formation was compared to basal. All samples were
incubated for 30 min at 307C unless otherwise indicated. CE and
radioactivity assay conditions are described in Section 2.
greater precision than the radioactivity assay; the largest peak
area RSD for the radioactivity assay is approximately double
(22%) compared to the CE-UV assay (12%).
In a drug screen-type experiment, the CE-UV assay may
be used by mixing the membranes with drugs, and then
quenching the reaction for readout by CE. To test this mode
of operation, AC membranes were incubated with various
modulators and the amount of cAMP formed after 30 min
was measured using an automated system (Fig. 3C). FSK
and Gas-GTPgS increased the amount of cAMP formed by
253 6 7 and 472 6 10%, respectively, compared to basal
(n = 4), yielding Z0 values [44] of 0.5 and 0.7, respectively. The
Z0 value measures the quality of a high-throughput assay,
and a value above 0.5 is considered an excellent assay [44].
Therefore, the CE-UV assay has sufficient reproducibility
and S/N for high-throughput screening. The P-site inhibitor
20,50-dd-30-ADP only produced 28 6 1% of the basal signal
(Z0 = 0.5, n = 4), also demonstrating the ability of the CE-UV
assay to detect AC inhibition. DMSO (0.5%; vehicle for FSK)
had no effect on basal cAMP rate formation (data not
shown).
3.5 GPCR drug screening using the CE-UV assay
GPCRs are more customary drug targets than AC, so this
assay was tested for its ability to detect agonist-activation at
the GPCR level using membranes coexpressing b2ARGasL
and AC (b2ARGasL-AC). Addition of b2AR agonists was
expected to increase the rate of cAMP formation as pre-
viously demonstrated [15, 45–47]. Figure 4 shows incubating
b2ARGasL-AC membranes with substrate and increasing
amounts of terbutaline (a specific b2AR agonist) resulted in a
1.7 6 0.1-fold maximal increase in the rate of cAMP forma-
tion and revealed a sigmoidal dose–response curve with an
EC50 of 62 6 10 nM (n = 4).
Figure 4. Rates of cAMP formation can be modulated with GPCR
drugs. Samples containing 30 mg b2ARGasL-AC membrane, ATP,
25 mM GTP, and 0–100 mM terbutaline were incubated in the
presence (u) or absence (n) of 100 nM propranolol. EC50s were
determined by fitting dose–response data. Error bars are smaller
than the data points. Results are representative of at least two
experiments. Sample preparation and CE details are described in
Section 2.
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The assay was next tested for its ability to detect antago-
nists binding to the receptor. Addition of a fixed amount of
antagonist should shift the agonist dose–response curve to
the right in cases where agonist and antagonists compete for
the same binding site. Figure 4 shows that the terbutaline
dose–response curve was right-shifted in the presence of
100 nM propranolol (b2AR antagonist), resulting in EC50 of
27 6 1 mM (n = 2). As expected, addition of 50 nM propra-
nolol resulted in a smaller right shift with and EC50 of
17 6 2 mM (n = 2, data not shown). These results demon-
strate that this assay can be used to screen both agonists and
antagonists.
In the same manner as modulators for AC were screened
(Fig. 3C), agonists for various GPCRs were incubated with
b2ARGasL-AC membranes and cAMP formation was meas-
ured. The amount of cAMP formed after 30 min was accel-
erated in the presence of b2AR agonists isoproterenol
(165 6 5%, Z0 = 0.4) and terbutaline (171 6 8%, Z0 = 0.5).
As negative controls, the effects of a2-adrenergic receptor
agonist UK 14 304 (n = 4) and dopamine 3 receptor agonist
PD 128 907 (n = 4) were tested and found to have no effects
(98 6 2 and 102 6 2%, respectively) as expected.
3.6 Advantages and limitations of CE-UV assay
The CE-UV assay addresses many of the disadvantages asso-
ciated with the radioactivity, RIA, and EIA techniques for
measuring AC activity. Coupling CE with UVdetection allows
nucleotides to be separated and detected, eliminating the
need for radioactive substrate used in the radiochemical assay.
Furthermore, the cost of the assay is reduced because the CE-
UV assay does not require special reagents or filtering steps.
Eliminating the filtering step also reduces assay time (by
removing washing steps), allows acquisition of kinetic infor-
mation (same sample can be serially injected), and makes the
assay more amenable to robotic operation. Similar to the
radioactivity assay, the linear dynamic range of the CE-UV
assay is several orders of magnitude larger than that of the
RIA or EIA, and is limited by enzyme kinetics (i.e., substrate
depletion) rather than the assay itself. The results presented
herein indicate that the CE-UV assay has greater precision
than the radioactivity assay. Furthermore, the combined sam-
ple preparation and analysis involved in the CE-UV assay is
less labor intensive than more traditional techniques.
Although multiplexed CE systems were initially
designed for DNA sequencing [48–50], they have recently
been used for increasing throughput in CE drug screening
assays [51]. For example, He and Yeung [51] used a 48-capil-
lary array system to improve throughput for the determina-
tion of six IC50 values (screening three inhibitors vs. two
enzymes). Transferring the AC assay described herein to a
capillary 96-array system would drastically improve
throughput for screening both AC and GPCR modulators.
Furthermore, if a hit is present in a screen, it should be
readily identified because the assay has Z0 values in the range
of 0.4–0.7.
Use of microgram quantities of membranes over-
expressing AC is common in radioactivity assays [36, 40], and
the CE-UV assay provided sufficient sensitivity to detect AC
activity under these conditions. Detection difficulties could
arise in samples expressing physiological levels of AC. Using
an S/N of 3, the LOD was ,1 mM cAMP (,30 fmol of
cAMP). For tissue samples with low AC activity, sample
stacking (oncolumn concentration) techniques could be
implemented to increase the cAMP signal [52–54], or assay
conditions could be altered (longer reaction times, more
protein/tube) to increase cAMP production and allow relia-
ble cAMP detection and quantification.
In recent work, we have used a fluorescent substrate and
CE with LIF to detect the activity of purified AC [55]. This
work differs substantially in that we do not require a special
fluorescent substrate and in that we use the assay with
enzymes still bound to the membrane. This allows us to
detect GPCR activity that is coupled to the AC enzyme. These
modifications make the assay of greater interest for potential
drug screening.
4 Concluding remarks
CE separation coupled with UV detection allowed the rapid
and automatable detection of AC activity in cell membranes.
CE eliminates the need for manual column chromatography
and washing steps, and UV detection allows the use of native,
radioactive-free substrate alleviating safety and cost concerns
surrounding the radioactivity assay. When the CE-UV and
radioactivity assays were directly compared, similar EC50
values and stimulation increases were obtained demonstrat-
ing the validity of the CE-UV assay. Detection of agonist-
mediated GPCR activation suggests that the assay has pro-
mise in drug screening applications.
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